The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study.
 
Paul D. Nathan
Consulting or Advisory Role - 4SC; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD; Novartis
Research Funding - Immunocore (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore; MSD
 
Jennifer Allison
Honoraria - Bristol-Myers Squibb
Travel, Accommodations, Expenses - EUSA Pharma
 
Natalie Charnley
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Pfizer
Research Funding - Bristol-Myers Squibb
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Richard Griffiths
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Pfizer
Consulting or Advisory Role - Eisai
 
Agnieszka Michael
Consulting or Advisory Role - EUSA Pharma; GlaxoSmithKline; GlaxoSmithKline; Ipsen; Ipsen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Merck
 
Kathryn Moore
No Relationships to Disclose
 
Anand Sharma
Consulting or Advisory Role - BMS; MSD Oncology
Speakers' Bureau - BMS GmbH & Co. KG; Eisai/MSD; EUSA Pharma; ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Pfizer/EMD Serono
Travel, Accommodations, Expenses - EUSA Pharma; EUSA Pharma; Ipsen; MSD
 
Bernadett Szabados
Honoraria - Ellipses Pharma; Ipsen; Merck; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Balaji Venugopal
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck; MSD Oncology; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer/EMD Serono
Speakers' Bureau - Eisai; Ipsen; Janssen Oncology; MSD Oncology; Pfizer
Research Funding - Calithera Biosciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - EUSA Pharma; Ipsen
 
Jamshed Ali
No Relationships to Disclose
 
Valérie Perrot
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Áine Prendergast
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Bhupinder Klair
Employment - Ipsen
Stock and Other Ownership Interests - Alcon; Allogene Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Galapagos NV; Gilead Sciences; Ipsen; Johnson & Johnson; Merck; Moderna Therapeutics; Novartis; Replimune; Sio Gene Therapies
 
James Larkin
Honoraria - Agence Unik; Bristol-Myers Squibb; Cambridge Healthcare research; Eisai; Incyte; Merck Serono; Novartis; Pfizer; RCGP; Royal College of Physicians; touchEXPERTS; touchIME; VJOncology
Consulting or Advisory Role - Agence Unik; Apple Tree Partners; Aptitude Health; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Debiopharm Group; eCancer; Eisai; EUSA Pharma; GlaxoSmithKline; Goldman Sachs; Incyte; Insel Gruppe; iOnctura; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Ultimovacs
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; GlaxoSmithKline; immatics; Pierre Fabre; Roche/Genentech